Androgen Receptor Signaling Inhibitors in Non‐Metastatic Castration‐Resistant Prostate Cancer in Japan: The <scp>ARASHI</scp> Study
We observed that a higher proportion of patients receiving darolutamide were likely to stay on treatment longer than patients receiving enzalutamide or apalutamide, and progression to mCRPC appeared to be delayed in these patients.
Authors
- Nasreen Khan (ORCID: https://orcid.org/0000-0001-6184-0503)
- Mercedeh Ghadessi (ORCID: https://orcid.org/0000-0003-1545-1499)
- Vanessa Quintero
- Kazuhiro Suzuki (ORCID: https://orcid.org/0000-0002-1448-7273)
- Niculae Constantinovici
- Guifang Chen
- Kana Hattori
- Hiroyoshi Suzuki (ORCID: https://orcid.org/0000-0001-5838-114X)
- Tomoyuki Taguchi
Institutions
- Toho University (JP)
- Bayer (United States) (US)
- Gunma University (JP)
- Bayer (Switzerland) (CH)
- Toho University Medical Center Sakura Hospital (JP)
- Bayer (Japan) (JP)
Publication Details
- Journal
- International Journal of Urology
- Published
- 2025-10-03
- DOI
- https://doi.org/10.1111/iju.70235
- Citations
- 2
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 3.04
Funders
- Bayer HealthCare